132 related articles for article (PubMed ID: 35585735)
1. In silico evaluation of atazanavir as a potential HIV main protease inhibitor and its comparison with new designed analogs.
Yoosefian M; Moghani MZ; Juan A
Comput Biol Med; 2022 Jun; 145():105523. PubMed ID: 35585735
[TBL] [Abstract][Full Text] [Related]
2. X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.
Klei HE; Kish K; Lin PF; Guo Q; Friborg J; Rose RE; Zhang Y; Goldfarb V; Langley DR; Wittekind M; Sheriff S
J Virol; 2007 Sep; 81(17):9525-35. PubMed ID: 17537865
[TBL] [Abstract][Full Text] [Related]
3. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
4. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
Alcaro S; Artese A; Ceccherini-Silberstein F; Ortuso F; Perno CF; Sing T; Svicher V
J Chem Inf Model; 2009 Jul; 49(7):1751-61. PubMed ID: 19537723
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
[TBL] [Abstract][Full Text] [Related]
7. GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
Salcedo Gómez PM; Amano M; Yashchuk S; Mizuno A; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 Dec; 57(12):6110-21. PubMed ID: 24080647
[TBL] [Abstract][Full Text] [Related]
8. (Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration.
Subbaiah MAM; Ramar T; Subramani L; Desai SD; Sinha S; Mandlekar S; Jenkins SM; Krystal MR; Subramanian M; Sridhar S; Padmanabhan S; Bhutani P; Arla R; Kadow JF; Meanwell NA
Eur J Med Chem; 2020 Dec; 207():112749. PubMed ID: 33065417
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics and ligand docking of a hinge region variant of South African HIV-1 subtype C protease.
Zondagh J; Balakrishnan V; Achilonu I; Dirr HW; Sayed Y
J Mol Graph Model; 2018 Jun; 82():1-11. PubMed ID: 29625416
[TBL] [Abstract][Full Text] [Related]
10. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of a potent substrate analog inhibitor identified by scanning Ala/Phe mutagenesis, mimicking substrate co-evolution, against multidrug-resistant HIV-1 protease.
Yedidi RS; Muhuhi JM; Liu Z; Bencze KZ; Koupparis K; O'Connor CE; Kovari IA; Spaller MR; Kovari LC
Biochem Biophys Res Commun; 2013 Sep; 438(4):703-8. PubMed ID: 23921229
[TBL] [Abstract][Full Text] [Related]
12. Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.
Mata-Munguía C; Escoto-Delgadillo M; Torres-Mendoza B; Flores-Soto M; Vázquez-Torres M; Gálvez-Gastelum F; Viniegra-Osorio A; Castillero-Manzano M; Vázquez-Valls E
BMC Bioinformatics; 2014 Mar; 15():72. PubMed ID: 24629078
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1' ligand.
Dou Y; Zhu M; Dong B; Wang JX; Zhang GN; Zhang F; Wang YC
Bioorg Med Chem Lett; 2020 Apr; 30(7):127019. PubMed ID: 32057582
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Nine Compounds Isolated from the Acid Hydrolysate of
Wang X; Wei Y; Tian WY; Sakharkar MK; Liu Q; Yang X; Zhou YZ; Mou CL; Cai GL; Yang J
Molecules; 2019 Dec; 24(24):. PubMed ID: 31835661
[TBL] [Abstract][Full Text] [Related]
15. A Combination of Novel HIV-1 Protease Inhibitor and Cytochrome P450 (CYP) Enzyme Inhibitor to Explore the Future Prospective of Antiviral Agents: Evotaz.
Sharma A; Sharma P; Kapila I; Abbot V
Curr HIV Res; 2023; 21(3):149-159. PubMed ID: 37221692
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors.
Khedkar VM; Ambre PK; Verma J; Shaikh MS; Pissurlenkar RR; Coutinho EC
J Mol Model; 2010 Jul; 16(7):1251-68. PubMed ID: 20069323
[TBL] [Abstract][Full Text] [Related]
17. A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy.
Naccarato M; Hall E; Wai A; Ostrowski M; Carvalhal A
Antivir Ther; 2016; 21(8):735-738. PubMed ID: 27328703
[TBL] [Abstract][Full Text] [Related]
18. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
[TBL] [Abstract][Full Text] [Related]
19. Advances in automated docking applied to human immunodeficiency virus type 1 protease.
Miller MD; Sheridan RP; Kearsley SK; Underwood DJ
Methods Enzymol; 1994; 241():354-70. PubMed ID: 7854188
[No Abstract] [Full Text] [Related]
20. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
